New Anticoagulant May Cut VTE In Medically Ill

–Generally positive results for Portola’s betrixaban, despite missed key endpoint Betrixaban may yet become the first new oral anticoagulant to gain approval for extended venous thromboembolism (VTE) prophylaxis in the important and underserved group of medically-ill patients, even though its pivotal trial was damaged by a self-inflicted statistical wound. There were consistent differences in favor of...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Prevention, Epidemiology & Outcomes anticoagulants betrixaban medical patients oral antcoagulant VTE Source Type: blogs